BIOX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Bioceres Crop Solutions Corp (BIOX) is not a strong buy at the moment for a beginner investor with a long-term strategy. Despite a recent price increase and positive MACD momentum, the company's poor financial performance, lack of significant trading trends, and absence of positive catalysts make it a less favorable investment choice currently. Holding off for now is recommended.
The MACD histogram is positive at 0.0248 and expanding, indicating bullish momentum. RSI is at 75.568, in the neutral zone, with no clear overbought or oversold signal. Moving averages are converging, showing no strong directional trend. Key resistance levels are at 0.627 and 0.67, with support levels at 0.486 and 0.443.
MACD shows positive momentum, and the stock has experienced a 10.11% regular market change, indicating short-term bullish sentiment.
Revenue dropped by -25.49% YoY, net income declined significantly (-127622.78% YoY), and gross margin decreased by -14.47% YoY. No significant trading trends from hedge funds or insiders. No recent news or congress trading data to support a positive outlook.
In Q2 2026, the company reported a revenue drop of -25.49% YoY to $73,674,526. Net income plummeted by -127622.78% YoY to -$183,039,821. EPS remained at -2.88, with no YoY improvement. Gross margin fell by -14.47% YoY to 36%. Overall, the financial performance is poor, with declining growth trends.
No recent analyst ratings or price target changes available for BIOX.
